Cargando…
Model-Based Drug Development in Pulmonary Delivery: Pharmacokinetic Analysis of Novel Drug Candidates for Treatment of Pseudomonas aeruginosa Lung Infection
Antibiotic resistance is a major public health threat worldwide. In particular, about 80% of cystic fibrosis patients have chronic Pseudomonas aeruginosa (PA) lung infection resistant to many current antibiotics. We are therefore developing a novel class of antivirulence agents, quorum sensing inhib...
Autores principales: | Sou, Tomás, Kukavica-Ibrulj, Irena, Soukarieh, Fadi, Halliday, Nigel, Levesque, Roger C., Williams, Paul, Stocks, Michael, Cámara, Miguel, Friberg, Lena E., Bergström, Christel A.S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307981/ https://www.ncbi.nlm.nih.gov/pubmed/30257195 http://dx.doi.org/10.1016/j.xphs.2018.09.017 |
Ejemplares similares
-
Hit Identification of New Potent PqsR Antagonists as Inhibitors of Quorum Sensing in Planktonic and Biofilm Grown Pseudomonas aeruginosa
por: Soukarieh, Fadi, et al.
Publicado: (2020) -
Design of Quorum
Sensing Inhibitor–Polymer
Conjugates to Penetrate Pseudomonas aeruginosa Biofilms
por: Soukarieh, Fadi, et al.
Publicado: (2023) -
Model-Informed Drug Discovery and Development in Pulmonary
Delivery: Biopharmaceutical Pharmacometric Modeling for Formulation
Evaluation of Pulmonary Suspensions
por: Sou, Tomás, et al.
Publicado: (2020) -
Genomics of antibiotic‐resistance prediction in Pseudomonas aeruginosa
por: Jeukens, Julie, et al.
Publicado: (2017) -
Molybdate transporter ModABC is important for Pseudomonas aeruginosa chronic lung infection
por: Périnet, Simone, et al.
Publicado: (2016)